SIMMYUNG YOOK

Dr. SIMMYUNG YOOK


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Acta Biomaterialia
Verified
Journal Article
Closed access
ABAsmita Banstola
Asmita Banstola
JJJee-Heon Jeong
Jee-Heon Jeong
SYSIMMYUNG YOOK
SIMMYUNG YOOK

6 April 2022 in Journal of Controlled Release
Verified
Journal Article
Closed access
NKNikita Katila
Nikita Katila
RDRamesh Duwa
Ramesh Duwa
SBSunil Bhurtel
Sunil Bhurtel
SKShristi Khanal
Shristi Khanal
SMSrijan Maharjan
Srijan Maharjan
SYSIMMYUNG YOOK
SIMMYUNG YOOK

22 August 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
PSPrabhat Shrestha
Prabhat Shrestha
NKNikita Katila
Nikita Katila
SLSooyeun Lee
Sooyeun Lee
JSJi Hae Seo
Ji Hae Seo
JJJee-Heon Jeong
Jee-Heon Jeong
SYSIMMYUNG YOOK
SIMMYUNG YOOK
Methamphetamine (MA) is a extremely addictive psychostimulant drug with a significant abuse potential. Long-term MA exposure can induce neurotoxic effects through oxidative stress, mitochondrial functional impairment, endoplasmic reticulum stress, the activation of astrocytes and microglial cells, axonal transport barriers, autophagy, and apoptosis. However, the molecular and cellular mechanisms underlying MA-induced neurotoxicity remain unclear. MA abuse increases the chances of developing neurotoxic conditions such as Parkinson's disease (PD), Alzheimer's disease (AD) and other neurotoxic diseases. MA increases the risk of PD by increasing the expression of alpha-synuclein (ASYN). Furthermore, MA abuse is linked to high chances of developing AD and subsequent neurodegeneration due to biological variations in the brain region or genetic and epigenetic variations. To date, there is no Food and Drug Administration (FDA)-approved therapy for MA-induced neurotoxicity, although many studies are being conducted to develop effective therapeutic strategies. Most current studies are now focused on developing therapies to diminish the neurotoxic effects of MA, based on the underlying mechanism of neurotoxicity. This review article highlights current research on several therapeutic techniques targeting multiple pathways to reduce the neurotoxic effects of MA in the brain, as well as the putative mechanism of MA-induced neurotoxicity.

1 September 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
ABAsmita Banstola
Asmita Banstola
KPKishwor Poudel
Kishwor Poudel
JKJong Oh Kim
Jong Oh Kim
JJJee-Heon Jeong
Jee-Heon Jeong
SYSIMMYUNG YOOK
SIMMYUNG YOOK

1 January 2019 in Drug Delivery
Verified
Journal Article
Open access
ABAsmita Banstola
Asmita Banstola
TPTung Thanh Pham
Tung Thanh Pham
JJJee-Heon Jeong
Jee-Heon Jeong
SYSIMMYUNG YOOK
SIMMYUNG YOOK
Chemotherapeutic drugs often used as a first-line treatment of pancreatic cancer (PC) exhibit challenges due to resistance development, lack of selectivity, and tumor heterogeneity. Currently, combination chemo-photothermal therapy is known to enhance the therapeutic efficacy of chemotherapeutic drugs in PC. In this study, we develop adherent gold nanoparticles (GNPs) and paclitaxel (PTX)-loaded PLGA microspheres for the treatment of PC. Polydopamine (pD) was used as a linker to adhere GNPs to the surface of PLGA-Ms and characterized using TEM. Short-term cytotoxicity of GNPs-pD-PTX-PLGA-Ms with or without NIR treatment was evaluated using CCK-8 assays. ROS and western blot assay were performed to determine the intensity of ROS following the treatment of GNPs-pD-PTX-PLGA-Ms with or without NIR in Panc-1 cell line. Successful adhesion of GNPs on the microspheres was confirmed by TEM. CCK-8 assay revealed that GNPs-pD-PTX-PLGA-Ms with NIR showed three-fold higher cytotoxicity, compared to the group without NIR. Furthermore, ROS and western blot assay suggest that GNPs-pD-PTX-PLGA-Ms with NIR showed more ROS generation, followed by downregulation of the expression levels of antioxidant enzyme (SOD2 and CATALASE). These results suggest that the GNPs-pD-PTX-PLGA-Ms in combination with NIR irradiation can provide a synergistic chemo-photothermal therapy for the treatment of PC.

1 January 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
Fakhrossadat EmamiFakhrossadat Emami
Fakhrossadat Emami
SPShiva Pathak
Shiva Pathak
TNTiep Tien Nguyen
Tiep Tien Nguyen
PSPrakash Shrestha
Prakash Shrestha
SMSrijan Maharjan
Srijan Maharjan
SYSIMMYUNG YOOK
SIMMYUNG YOOK